Immedica announces first marketing authorization approval in the MENA region

The new research hub in Cambridge, Massachusetts, in the greater Boston area, will serve as Zealand Pharma’s primary US address and is expected to be operational from September 2026.

Diamyd Medical have announced the completion of a pre-specified interim efficacy analysis on C-peptide in the ongoing Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in individuals with recent-onset Stage 3 type 1 diabetes carrying the HLA DR3-DQ2 haplotype. The interim analysis that included 174 out of 321 study participants did not demonstrate statistical significance on […]

Mendus has entered into an agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI), an Australian cancer research institute, to support the DIVA trial with the company’s lead product vididencel in acute myeloid leukemia (AML).

The company is opening of a new 8,000-square-meter center supporting its immunodiagnostics business in Uppsala.

Through the directed issue, the company will receive approximately SEK 51.9 million.

The Board of Directors has resolved to carry out a new share issue of approximately SEK 200 million with preferential rights for the company’s existing shareholders based on the authorization granted by the Annual General Meeting on 22 May 2025.

A Letter of Intent (LOI) has been signed with SHINE Technologies as an additional supplier of non-carrier-added Lutetium-177 (n.c.a. Lu-177).